Review
Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: A systematic review of the experience in industrialized countries
Downloads and Tools
Volume 7, Issue 7 July 2011
Pages 734 - 748
http://dx.doi.org/10.4161/hv.7.7.15511
Authors: Carlo Giaquinto, Geraldine Dominiak-Felden, Pierre Van Damme, Tin Tin Htar Myint, Yvonne A. Maldonado, Vana Spoulou, T. Christopher Mast and Mary Allen Staat
View affiliations Hide affiliations
- Carlo Giaquinto
-
Department of Pediatrics, University of Padova, Padova, Italy
- Geraldine Dominiak-Felden
-
Department of Epidemiology, Sanofi Pasteur MSD, 8 rue Jonas Salk, Lyon, France
- Pierre Van Damme
-
Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp, Belgium
- Tin Tin Htar Myint
-
Sanofi Pasteur MSD;Lyon, France
- Yvonne A. Maldonado
-
Department of Pediatrics, Stanford University School of Medicine; Stanford, CA USA
- Vana Spoulou
-
University of Athens, Athens, Greece
- T. Christopher Mast
-
Corresponding author: Christopher_mast@merck.com
Department of Epidemiology, Merck Research Laboratories, North Wales, PA USA
- Mary Allen Staat
-
8Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center; Cincinnati, OH USA
Abstract:
The pentavalent rotavirus (RV) vaccine RotaTeq™ has been available in industrialized countries since 2006. Several studies have been conducted to evaluate the benefit of RV vaccination under routine conditions of use. A systematic review of all publicly available data from RotaTeq™ vaccine-effectiveness and vaccination-impact studies in the USA, Europe and Australia between 2006 and February 2010 was undertaken. Depending on the population studied, effectiveness of up to 100% (95% confidence interval 85–100%) associated with decreased hospitalizations for RV gastroenteritis (RVGE) was seen. Vaccination-impact studies demonstrated that the burden of RVGE has been reduced significantly since the introduction of RV vaccination. Evidence included reductions in healthcare utilization due to RVGE (hospitalizations and emergency-department visits reduced by up to 90%), reductions in the magnitude and duration of the RV season as assessed by laboratory testing for RV, and the possible induction of herd immunity.
Received: December 22, 2010; Accepted: March 17, 2011
Preview: